365 related articles for article (PubMed ID: 17879265)
1. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression.
Fernagut PO; Hutson CB; Fleming SM; Tetreaut NA; Salcedo J; Masliah E; Chesselet MF
Synapse; 2007 Dec; 61(12):991-1001. PubMed ID: 17879265
[TBL] [Abstract][Full Text] [Related]
2. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
3. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration.
Manning-Bog AB; McCormack AL; Purisai MG; Bolin LM; Di Monte DA
J Neurosci; 2003 Apr; 23(8):3095-9. PubMed ID: 12716914
[TBL] [Abstract][Full Text] [Related]
4. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
[TBL] [Abstract][Full Text] [Related]
5. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
6. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
7. [Effects of different doses of levodopa on paraquat-induced neurotoxicity: an experiment with mice].
Du YL; Liu ZG; Chen SD; Lu GQ
Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(34):2400-3. PubMed ID: 16321246
[TBL] [Abstract][Full Text] [Related]
8. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH
Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690
[TBL] [Abstract][Full Text] [Related]
9. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.
Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
Neuroscience; 2012 Feb; 203():170-9. PubMed ID: 22198020
[TBL] [Abstract][Full Text] [Related]
10. Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat.
Hutson CB; Lazo CR; Mortazavi F; Giza CC; Hovda D; Chesselet MF
J Neurotrauma; 2011 Sep; 28(9):1783-801. PubMed ID: 21644813
[TBL] [Abstract][Full Text] [Related]
11. Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats.
Naughton C; O'Toole D; Kirik D; Dowd E
Behav Brain Res; 2017 Jan; 316():160-168. PubMed ID: 27585560
[TBL] [Abstract][Full Text] [Related]
12. Formation and Implications of Alpha-Synuclein Radical in Maneb- and Paraquat-Induced Models of Parkinson's Disease.
Kumar A; Leinisch F; Kadiiska MB; Corbett J; Mason RP
Mol Neurobiol; 2016 Jul; 53(5):2983-2994. PubMed ID: 25952542
[TBL] [Abstract][Full Text] [Related]
13. 7,8-dihydroxyflavone Ameliorates Motor Deficits Via Suppressing α-synuclein Expression and Oxidative Stress in the MPTP-induced Mouse Model of Parkinson's Disease.
Li XH; Dai CF; Chen L; Zhou WT; Han HL; Dong ZF
CNS Neurosci Ther; 2016 Jul; 22(7):617-24. PubMed ID: 27079181
[TBL] [Abstract][Full Text] [Related]
14. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
Coune PG; Bensadoun JC; Aebischer P; Schneider BL
J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
[TBL] [Abstract][Full Text] [Related]
15. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype.
Thiruchelvam M; McCormack A; Richfield EK; Baggs RB; Tank AW; Di Monte DA; Cory-Slechta DA
Eur J Neurosci; 2003 Aug; 18(3):589-600. PubMed ID: 12911755
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
[TBL] [Abstract][Full Text] [Related]
17. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
19. Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.
Kim HW; Choi WS; Sorscher N; Park HJ; Tronche F; Palmiter RD; Xia Z
Neurobiol Aging; 2015 Sep; 36(9):2617-27. PubMed ID: 26070241
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
